More than 20 billion dollars worth of biopharmaceuticals are scheduled to go off-patent by 2006. Given the strong political impetus and the development of technological tools that can answer the questions regulatory authorities may raise, it is inevitable that the FDA and EMEA will allow biogeneric or biosimilar products. Even with all the regulato
Compre este e-book e ganhe mais 1 GRÁTIS!
Língua Inglês ● Formato EPUB ● Páginas 584 ● ISBN 9781000611328 ● Editora CRC Press ● Publicado 2002 ● Carregável 3 vezes ● Moeda EUR ● ID 7050352 ● Proteção contra cópia Adobe DRM
Requer um leitor de ebook capaz de DRM